Form 4: PLUS Therapeutics CFO Granted Equity Awards

PLUS Therapeutics' Chief Financial Officer, Andrew Sims, was granted stock options and restricted stock units.

Summary

• Andrew John Hugh MacIntyre Sims, Chief Financial Officer of PLUS THERAPEUTICS, INC. (PSTV), was granted equity awards.
• The awards include 1,379,636 stock options with an exercise price of $0.5744 per share.
• These stock options vest over four years in equal 1/48th increments on each monthly anniversary of the issuance date.
• Additionally, 459,878 Restricted Stock Units (RSUs) were granted.
• The RSUs vest over three years, with 1/3rd vesting on the first anniversary of the grant date and the remaining 2/3rds vesting in equal monthly installments over the subsequent two years.
• Upon vesting, the RSUs convert into shares of Common Stock on a one-for-one basis.
• The transaction date for these grants was August 13, 2025, with the filing submitted on August 15, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates management alignment with shareholder interests and a commitment to executive retention. However, it is a routine compensation event and does not reflect new operational achievements or financial performance.

Positives

• The equity grants align the Chief Financial Officer's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedules for both stock options and RSUs serve as a retention mechanism for key management personnel.

Future Outlook

The equity awards granted to the Chief Financial Officer are structured with multi-year vesting schedules, indicating a long-term commitment to the company's performance and executive retention. The stock options will vest monthly over four years, and the Restricted Stock Units will vest over three years, with an initial one-third vesting on the first anniversary and the remainder monthly over the subsequent two years.

Industry Context

The granting of stock options and restricted stock units to executive officers is a standard practice in the biotechnology and pharmaceutical industries. This form of compensation is widely used to attract, retain, and motivate key talent by aligning their financial interests with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The structure of the equity compensation, including multi-year vesting periods for both stock options and RSUs, is consistent with typical executive compensation packages observed across the biotechnology and pharmaceutical sectors.
• The use of both stock options (performance-based with exercise price) and RSUs (value-based upon vesting) is a common approach to provide a balanced incentive structure for executives in growth-oriented companies like PLUS Therapeutics.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of management's interests with long-term shareholder value creation.
• Employees: No direct impact on general employees, but may signal stability in executive leadership.
• Management: Direct positive impact through increased equity ownership and potential future compensation.

Next Steps

• Continued vesting of stock options and Restricted Stock Units according to their respective schedules over the next three to four years.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation grants and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure of an insider transaction.

Keywords

PLUS Therapeutics, PSTV, Andrew Sims, CFO, Stock Options, Restricted Stock Units, RSUs, Equity Compensation, Insider Transaction, SEC Form 4, Executive Compensation